Asset profile
JK07
Biologic — subtype unspecified
Evidence outlook · lead readout
NCT04210375 · Heart Failure With Reduced Ejection Fraction
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04210375: This trial randomized a small number of heart-failure patients to JK07 or placebo under full blinding, but it measured only safety, not efficacy, and the dose cohorts were very small (3-4 patients each). A death occurred in one of the JK07 dose groups during the study.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.